Biotech

Selected news for the healthcare topic - Biotech, collected since 10/2017. Recent stories appear in theonlinetradingmentor.com and biovoicenews.com. This healthcare topic shares news with COVID-19, Pfizer, Food and Drug Administration, Novartis, Merck and hundreds of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
2/23/2021 Is Galapagos Stock a Bad-News Buy Right Now? theonlinetradingmentor.com February 23, 2021This post was originally published and is credit to this siteYou won’t find many biotech stocks that have upset as many investors over the past year as Galapagos (NASDAQ: GLPG) . In fact, shareholders voicing their disappointment have pushed the stock into the dirt.© Provided by The Motley Fool Is Galapagos Stock a Bad-News Buy Right Now?Galapagos shares have tumbled so far that coolheaded ...
2/23/2021 Windlas Biotech & Mateon Therapeutics launch India's first combined lung therapy & Ai Telemedicine 360 Solution to transform respiratory wellness biovoicenews.com Windlas Biotech & Mateon Therapeutics launch India’s first combined lung therapy & Ai Telemedicine 360 Solution to transform respiratory wellness The combined drug + AI telemedicine 360 solution is being launched to transform respiratory illness 0 17 New Delhi: Windlas Biotech, a leading Indian pharmaceutical contract drug development and manufacturing organization, in partnership with Mateon Therapeutics, Inc. (Mateon), a US-based oncology company focusing on TGF-β inhibitors as therapies against cancers ...
2/23/2021 ERS Genomics Licenses CRISPR Patents to Korean Biotech Firm G+FLAS Life Sciences genomeweb.com NEW YORK – ERS Genomics said on Tuesday that it has granted biotechnology company G+FLAS Life Sciences of South Korea a non-exclusive license to its CRISPR-Cas9 patent portfolio, which G+FLAS said it will use to provide services and tools as well as to develop drugs and produce genome edited plants.Financial and other terms of the deal were not disclosed ...
2/23/2021 The Ridgway Record ridgwayrecord.com ... manageable living with the disease. Key Players such as BrainStorm Cell Therapeutics, Apellis Pharmaceuticals, Biogen, Alsonex Pharmaceuticals, Astellas Pharma, Grifols Therapeutics, AL-S Pharma, Genuv, Annexon, Mitsubishi Tanabe Pharma Corporation, Q Therapeutics, Acurastem, Everfront Biotech Co. Ltd, MediciNova, Novartis, Amylyx Pharmaceuticals Inc., Orphazyme , and many others are developing therapies that are focused on novel approaches to treat Amyotrophic Lateral Sclerosis. The U.S. Food and Drug Administration (FDA) has authorized the ...
2/23/2021 Recent Analysis on Amyotrophic Lateral Sclerosis Clinical Trials Globe Newswire ... manageable living with the disease. Key Players such as BrainStorm Cell Therapeutics, Apellis Pharmaceuticals, Biogen, Alsonex Pharmaceuticals, Astellas Pharma, Grifols Therapeutics, AL-S Pharma, Genuv, Annexon, Mitsubishi Tanabe Pharma Corporation, Q Therapeutics, Acurastem, Everfront Biotech Co. Ltd, MediciNova, Novartis, Amylyx Pharmaceuticals Inc., Orphazyme , and many others are developing therapies that are focused on novel approaches to treat Amyotrophic Lateral Sclerosis. The U.S. Food and Drug Administration (FDA) has authorized the ...
2/23/2021 Where Will Biogen Be in 5 Years? fool.com Search: Where Will Biogen Be in 5 Years? The biotech has a lot riding on whether the FDA approves its potential Alzheimer's treatment, aducanumab. (TMFjimhalley) Feb 23, 2021 at 6:30AM This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think ...
2/23/2021 Chromatography Instruments Market worth $11.0 billion by 2025 – Express Press Release Distribution express-press-release.net Posted on 2021-02-23 by MarketsandMarkets in Biotech , Healthcare , Pharmaceuticals // 0 CommentsPune , India , 2021-Feb-23 — /EPR Network/ —The growing investments in the pharmaceutical R&D, rising food safety concerns, increasing adoption of gas chromatography in oil & gas industry and policies to reduce environmental pollution levels are the key drivers of the chromatography instruments market growth. Increasing burden on healthcare systems owing to the COVID-19 pandemic worldwide ...
2/23/2021 Global Competent Cells Market 2020 With COVID-19 Update | Merck KGaA, Yeastern Biotech, Takara Bio, Thermo Fisher Scientific themarketcorrespondent.com ... The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry. request/98198Key list market participants in the market: Merck KGaA, Yeastern Biotech, Takara Bio, Thermo Fisher Scientific, GeneScript Corporation, Agilent Technologies, QIAGEN N.V., Beijing TransGen Biotech, Promega Corporation, New England Biolabs, Bioline, Cell Applications, OriGene Technologies, Scarab Genomics, Delphi Genetics, Bio-Rad Laboratories, Lucigen, BioDynamics Laboratory, IBA ...
2/23/2021 Beam makes $120M bet that GuideTx's tech brings gene editing beyond the liver MedCity News BioPharma , Pharma , SYN Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver ...
2/23/2021 Gene editing biotech Beam adds to drug delivery stable with $120M GuideTx buy FierceBiotech ... royalties on treatments that use its tech. Beam went on to raise another $135 million in venture capital before turning to the public markets in its $180 million IPO in February 2020.RELATED: Fierce Biotech's 2018 Fierce 15 Beam TherapeuticsThe company tagged the IPO proceeds for IND-enabling studies and clinical trials for “certain” programs in its pipeline, as well as support R&D for its preclinical-stage ...
2/23/2021 Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going FierceBiotech Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial. The series C positions the Chinese biotech to validate the efficacy of its vaccine and gear up to manufacture hundreds of millions of doses this year.Last month, Clover researchers published data from a phase 1 clinical trial of their COVID-19 prospect in The Lancet. The paper featured safety, tolerability ...
2/23/2021 Merck KGaA offloads clinical-phase cancer drugs to Day One FierceBiotech ... opted against taking the asset deeper into the clinic. The Big Pharma terminated the only clinical trial of MSC2015103B for “an administrative reason.” Day One sees reasons to restart development. The California-based biotech plans to run a phase 1/2 clinical trial that will test pimasertib, a drug given to around 900 patients to date, in combination with its existing type II pan-RAF kinase inhibitor DAY101. The study ...
2/23/2021 Intercept loses chief medical officer months after CEO stepped down FierceBiotech ... Gail Cawkwell, M.D., Ph.D., will serve as acting CMO.This all comes amid a tough time for the company, though, a few years ago, things looked a lot brighter. Intercept is no pre-revenue biotech ; it has a commercial asset in obeticholic acid, which is approved in primary biliary cholangitis (PBC) as Ocaliva, nabbing a U.S. green light back in 2016.RELATED: Intercept cuts 25% of workforce after NASH rejection ...
2/23/2021 Alexion alums land at complement biotech Kira Pharma as it plots its course through the clinic | FierceBiotech FierceBiotech As Kira Pharma shepherds two more programs toward the clinic, the complement-focused biotech is bolstering its leadership team with a trio of biopharma veterans, including a pair of Alexion alums.Its new chief medical officer, Richard Lee, M.D. joins after AstraZeneca’s $39 billion buyout cut short his tenure as Alexion’s head of hematology, while chief commercial officer, Dana Zhang, M.D., arrives after nine years at the complement ...
2/23/2021 The Latest: Philippine leader won't ease virus restrictions Star Tribune ... have been set back by delays in the arrival of initial batches of COVID-19 vaccine, have been launched, presidential spokesman Harry Roque said. The scheduled delivery on Tuesday of 600,000 doses from Sinovac Biotech Ltd. was postponed anew after the China-based company failed to immediately secure an emergency-use permit from Manila's Food and Drug Administration. Sinovac got the authorization Monday. Top economic officials have asked Duterte to ...
2/23/2021 68 Biggest Movers From Yesterday | Markets Insider Business Insider ... Cooper Tire & Rubber Company (NYSE: CTB ) rose 29.4% to close at $56.64 after the company announced it will be acquired by Goodyear around $2.8 billion. Cooper Tire & Rubber also reported Q4 results. Burning Rock Biotech Limited (NASDAQ: BNR ) gained 25.3% to close at $39.58. The company announced plans to release its unaudited Q4 financial results before the U.S. market opens on March 11, 2021. Xcel Brands, Inc. (NASDAQ: XELB ) jumped ...
2/23/2021 Vitamin B Market to Exhibit Impressive Growth by 2025| Herbalife, Abbott laboratories, Amway, Pfizer, Fermenta Biotech Ltd., Bactolac Pharmaceutical picayunecurrent.com ... will experience a rapid growth because of increase in energy drink, cosmetic and pharmaceutical industries.Key players involved in the development of vitamin B and derivatives market are Herbalife, Abbott laboratories, Amway, Pfizer, Fermenta Biotech Ltd., Bactolac Pharmaceutical and more.Key Segments in the “Global Vitamin B and its derivatives Market” are-By Application market is segmented into: Food & Beverages ...
2/23/2021 Trending News: Lutein & Zeaxanthin Market Growth, Share, Analysis and Industry Forecast 2019 to 2025 | BASF, DSM, Chr. Hansen ccguardian.com ... form/form/785313/global-lutein-amp-zeaxanthin-industry-research-report-growth-trends-and-competitive-analysis-2018-2025Top Leading Players: BASF, DSM, Chr. Hansen, FMC, Kemin Industries, Cyanotech, Kemin Industries, D.D. Williamson, Dhler Group, Allied Biotech Corporation, ExcelViteGlobal Lutein & Zeaxanthin Market by Type: Lutein, ZeaxanthinGlobal Lutein & Zeaxanthin Market by Application: Supplements, Food, Feed, Cosmetics, Pharmaceuticals, Others By Peru]Lutein & Zeaxanthin request/form/785313/global-lutein-amp-zeaxanthin-industry-research ...
2/23/2021 News – Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is expected to report earnings of $ 0.27 per share w24news.com ... earnings per share are based on a survey of sell-side research firms involved in Brainstorm Cell Therapeutics.Brainstorm Cell Therapeutics (NASDAQ: BCLI) last announced on Wednesday, April 3rd. February, its results announced. The biotech company reported earnings per share of $ 0.37 for the quarter, beating Zacks’ consensus estimate of $ 0.48 by $ 0.11.Regardless, Maxim Group upgraded Brainstorm Cell Therapeutics from a “Hold” rating to a “Buy” ...
2/23/2021 HealthEconomics.Com's Value and Evidence Marketplace Seeking Organizations With EHR Data healtheconomics.com ... Organizations With EHR DataThe Value and Evidence Marketplace is an online tool that matches biomedical and biopharmaceutical researchers with suppliers for research. 24 of the top 30 pharmaceutical companies, along with over 75 biotech companies, utilize our Marketplaces in their studies. Clients are increasingly interested in studies involving EHR and claims data. If you are a solution provider or an organization with access to data, make sure you are ...